OssDsign Toekomstige groei
Future criteriumcontroles 2/6
OssDsign zal naar verwachting groeien in winst en omzet met respectievelijk 35.6% en 24.6% per jaar. De winst per aandeel zal naar verwachting groeien met 38.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -12.4% zijn.
Belangrijke informatie
35.6%
Groei van de winst
38.73%
Groei van de winst per aandeel
| Medical Equipment winstgroei | 21.3% |
| Inkomstengroei | 24.6% |
| Toekomstig rendement op eigen vermogen | -12.39% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 11 Aug 2026 |
Recente toekomstige groei-updates
Recent updates
Narratiefupdate • Jul 17
nan
Analysts have reduced their price target for OssDsign from SEK 17.50 to SEK 9.00, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. What’s in the News for OssDsign No recent OssDsign specific news items were identified in the provided sources.
Narratiefupdate • Jul 02
OSSD: Higher Margin Outlook And Lower P/E Will Support Future Re Rating
Analysts have adjusted their price target on OssDsign to SEK 6.40 from SEK 12.75, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple. What’s in the News for OssDsign OssDsign issued earnings guidance for the first quarter of 2026, indicating an expected loss before interest and taxes in the range of SEK 12.0 million to SEK 14.0 million, according to company guidance.
Narratiefupdate • Jun 18
OSSD: Refined Forecast Assumptions And Q1 2026 Guidance Support Upside Potential
Analysts have kept their OssDsign price target steady at SEK5.10, with only small tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E, which feed into an unchanged fair value view. What’s in the News for OssDsign OssDsign issued earnings guidance for the first quarter of 2026, indicating an expected loss before interest and taxes in a range of SEK 12.0 million to SEK 14.0 million.Narratiefupdate • Jun 04
OSSD: Refined Forecast Assumptions Will Support Future Upside Potential
Analysts have maintained their SEK fair value estimate for OssDsign while updating inputs such as revenue growth, profit margin, discount rate and a lower future P/E assumption. Together, these changes support a refined price target framework without altering the headline SEK figure.Narratiefupdate • May 03
OSSD: Higher Long Term Margins And Moderate P/E Will Support Future Upside
Analysts have revised their price target for OssDsign to SEK 5.1 from SEK 13.5. The change reflects updated assumptions around growth, profitability and a more moderate future P/E multiple. What's in the News OssDsign issued earnings guidance for the first quarter of 2026, indicating a loss before interest and taxes in the range of SEK 12.0 million to SEK 14.0 million, with only marginal exchange rate impact (Key Developments).Narratiefupdate • Apr 18
OSSD: Stable Loss Outlook And Assumptions Will Support Future Multiple Re Rating
Analysts have kept their OssDsign price target steady at SEK 12.75, indicating only marginal tweaks in the discount rate, long term revenue growth, profit margin and future P/E assumptions, rather than any major shift in their view of the company. What's in the News OssDsign issued earnings guidance for the first quarter of 2026, focusing on loss before interest and taxes rather than revenue or profit metrics.Narratiefupdate • Apr 04
OSSD: Stable Profitability Assumptions Will Support Future Multiple Re rating
Analysts keep their SEK 12.75 price target on OssDsign unchanged, citing steady assumptions around growth, margins, and a future P/E near 113x as the basis for maintaining the current valuation. Valuation Changes Fair Value: SEK 12.75 remains unchanged, so the target valuation level is consistent with prior assumptions.Narratiefupdate • Mar 20
OSSD: Stable Assumptions Will Support Long Term Margin Expansion
Analysts have maintained their SEK 12.75 price target for OssDsign, citing stable assumptions on fair value, discount rate, revenue growth, profit margin and future P/E as the basis for this unchanged view. Valuation Changes Fair Value: SEK 12.75 remains unchanged, signalling a stable central valuation estimate.Narratiefupdate • Mar 05
OSSD: New US Leadership Will Support Long Term Margin Expansion
Analysts have kept their OssDsign price target steady at SEK 12.75, citing largely unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for maintaining their view. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, following his senior roles at Smith & Nephew plc, Medtronic Sofamor Danek Inc, and Medacta USA (Key Developments).Narratiefupdate • Feb 19
OSSD: New US-Focused Leadership Will Support Long Term Margin Expansion
Analysts are maintaining their SEK 12.75 price target on OssDsign. They point to a slightly higher discount rate, broadly similar revenue growth assumptions at around 26%, a lower profit margin outlook, and a higher future P/E expectation as key inputs behind this unchanged view.Narratiefupdate • Feb 04
OSSD: US Leadership Change Will Support Long Term Margin Expansion
Analysts have reduced their price target on OssDsign to €12.75 from €15.50, citing updated assumptions for growth, margins, and a lower future P/E multiple. What's in the News OssDsign AB appointed Mark Waugh as CEO, with his tenure set to begin on January 1, 2026, following a leadership transition from current CEO Morten Henneveld (Key Developments).Narratiefupdate • Jan 20
OSSD: New US Based Leadership Will Drive Future Orthobiologics Expansion
Analysts have kept their price target for OssDsign steady at €13.50, citing only marginal adjustments to the discount rate, revenue growth, profit margin and forward P/E assumptions that together are not enough to shift their overall valuation view. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, following his senior roles at Smith & Nephew, Medtronic Sofamor Danek, and Medacta USA (company announcement).Narratiefupdate • Jan 06
OSSD: New US Focused Leadership Will Shape Bullish Future Outlook
Analysts have adjusted their price target on OssDsign to $13.50, reflecting updated assumptions around revenue growth, profit margin and a much higher implied future P/E multiple, while keeping their fair value estimate unchanged at $13.50. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, following five years of leadership under outgoing CEO Morten Henneveld (Key Developments).Narratiefupdate • Dec 13
OSSD: New Leadership And Index Inclusion Will Shape Balanced Future Outlook
The analyst price target for OssDsign has been raised from SEK 12.0 to SEK 13.5, as analysts factor in a higher long term valuation multiple despite slightly slower projected revenue growth and a softer profit margin profile. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, succeeding Morten Henneveld after five years of leading the company through growth and transformation (company announcement) New CEO Mark Waugh brings over 20 years of international leadership experience across major orthopedic segments in the USA and Europe, including senior roles at Smith & Nephew, Medtronic Sofamor Danek, and Medacta USA (company announcement) OssDsign Catalyst driven orthobiologics focus has supported strong double digit growth in the U.S. market since its launch in August 2021 (company announcement) OssDsign AB (publ) has been added to the S&P Global BMI Index, increasing its visibility to international institutional investors (index provider) Valuation Changes Fair Value: Raised from SEK 12.0 to SEK 13.5, reflecting a modest upward revision in the company’s long term valuation.Narratiefupdate • Aug 08
Pure Play Orthobiologics Will Expand US Healthcare Access
With OssDsign's consensus price target revised lower, primarily driven by a notable drop in its Future P/E from 77.22x to 64.47x, the fair value estimate has decreased from SEK15.67 to SEK14.83. What's in the News An undisclosed buyer acquired an unknown minority stake in OssDsign AB from Karolinska Development AB.Analyse-artikel • May 08
Optimistic Investors Push OssDsign AB (publ) (STO:OSSD) Shares Up 31% But Growth Is Lacking
OssDsign AB (publ) ( STO:OSSD ) shareholders would be excited to see that the share price has had a great month...
Nieuw narratief • Apr 07
Pure Play Orthobiologics Will Expand US Healthcare Access
Strategic shift to orthobiologics boosts growth and operational efficiency, enhancing future revenue and sustaining high net margins.Analyse-artikel • Feb 21
OssDsign AB (publ)'s (STO:OSSD) 25% Price Boost Is Out Of Tune With Revenues
OssDsign AB (publ) ( STO:OSSD ) shares have continued their recent momentum with a 25% gain in the last month alone...Analyse-artikel • Feb 07
Analysts Are Upgrading OssDsign AB (publ) (STO:OSSD) After Its Latest Results
OssDsign AB (publ) ( STO:OSSD ) defied analyst predictions to release its full-year results, which were ahead of market...Analyse-artikel • Nov 15
OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price
OssDsign AB (publ) ( STO:OSSD ) just released its latest quarterly results and things are looking bullish. OssDsign...Analyse-artikel • Nov 13
OssDsign AB (publ)'s (STO:OSSD) Share Price Matching Investor Opinion
OssDsign AB (publ)'s ( STO:OSSD ) price-to-sales (or "P/S") ratio of 5.7x might make it look like a sell right now...Analyse-artikel • Aug 23
OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price
Last week, you might have seen that OssDsign AB (publ) ( STO:OSSD ) released its quarterly result to the market. The...Analyse-artikel • Aug 06
We Think OssDsign (STO:OSSD) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analyse-artikel • Jun 19
Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now
Key Insights OssDsign's Annual General Meeting to take place on 25th of June CEO Morten Henneveld's total compensation...Analyse-artikel • Mar 19
Getting In Cheap On OssDsign AB (publ) (STO:OSSD) Is Unlikely
OssDsign AB (publ)'s ( STO:OSSD ) price-to-sales (or "P/S") ratio of 8.5x might make it look like a strong sell right...Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 316 | -13 | -45 | -28 | 3 |
| 12/31/2027 | 244 | -35 | -51 | -42 | 3 |
| 12/31/2026 | 171 | -49 | -66 | -48 | 3 |
| 3/31/2026 | 173 | -48 | -65 | -53 | N/A |
| 12/31/2025 | 180 | -51 | -71 | -64 | N/A |
| 9/30/2025 | 176 | -42 | -59 | -54 | N/A |
| 6/30/2025 | 168 | -46 | -57 | -53 | N/A |
| 3/31/2025 | 151 | -53 | -62 | -60 | N/A |
| 12/31/2024 | 134 | -50 | -63 | -62 | N/A |
| 9/30/2024 | 127 | -90 | -81 | -81 | N/A |
| 6/30/2024 | 123 | -114 | -91 | -91 | N/A |
| 3/31/2024 | 118 | -118 | -95 | -95 | N/A |
| 12/31/2023 | 112 | -130 | -94 | -94 | N/A |
| 9/30/2023 | 97 | -109 | -93 | -93 | N/A |
| 6/30/2023 | 83 | -95 | -93 | -93 | N/A |
| 3/31/2023 | 71 | -99 | -92 | -92 | N/A |
| 12/31/2022 | 57 | -99 | -86 | -86 | N/A |
| 9/30/2022 | 46 | -96 | -82 | -82 | N/A |
| 6/30/2022 | 38 | -93 | -98 | -98 | N/A |
| 3/31/2022 | 33 | -95 | -90 | -90 | N/A |
| 12/31/2021 | 32 | -94 | -90 | -90 | N/A |
| 9/30/2021 | 29 | -90 | -94 | -93 | N/A |
| 6/30/2021 | 27 | -92 | -77 | -76 | N/A |
| 3/31/2021 | 23 | -90 | -83 | -80 | N/A |
| 12/31/2020 | 25 | -85 | -82 | -79 | N/A |
| 9/30/2020 | 24 | -89 | -81 | -79 | N/A |
| 6/30/2020 | 22 | -89 | -90 | -88 | N/A |
| 3/31/2020 | 22 | -85 | -87 | -86 | N/A |
| 12/31/2019 | 18 | -84 | N/A | -87 | N/A |
| 9/30/2019 | 18 | -72 | N/A | -90 | N/A |
| 6/30/2019 | 20 | -66 | N/A | -75 | N/A |
| 3/31/2019 | 21 | -62 | N/A | -78 | N/A |
| 12/31/2018 | 21 | -56 | N/A | -66 | N/A |
| 12/31/2017 | 16 | -63 | N/A | -41 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat OSSD de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat OSSD de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat OSSD de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van OSSD ( 24.6% per jaar) zal naar verwachting sneller groeien dan de markt Swedish ( -1.4% per jaar).
Hoge groei-inkomsten: De omzet van OSSD ( 24.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat OSSD binnen 3 jaar verliesgevend zal zijn.
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/12 15:03 |
| Aandelenkoers aan het einde van de dag | 2026/08/12 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
OssDsign AB (publ) wordt gevolgd door 3 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | ABG Sundal Collier |
| null null | ABG Sundal Collier Sponsored |
| Kristofer Liljeberg-Svensson | DNB Carnegie Commissioned Research |